Latest News - Ocular Therapeutix

Wednesday, March 22, 2017 | Medical Studies, Ocular Therapeutix

New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ Dextenza Following Cataract Surgery

Ocular Therapeutix announced positive results of a patient experience study of Dextenza (dexamethasone insert) 0.4 mg for intracanalicular use. The study, published in Patient Preference and Adhe…

Read the full story

Wednesday, February 22, 2017 | Cataract Surgery, Ocular Therapeutix

Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenza for the Treatment of Ocular Pain After Ophthalmic Surgery

Ocular Therapeutix announced that the company’s new drug application (NDA) resubmission for Dextenza (dexamethasone insert) 0.4 mg for intracanalicular use for the treatment of ocular pain occur…

Read the full story

Monday, January 23, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Resubmits NDA for Dextenza for the Treatment of Ocular Pain After Ophthalmic Surgery

Ocular Therapeutix announced that it has resubmitted a new drug application (NDA) to the FDA for Dextenza (dexamethasone insert) 0.4 mg, for the treatment of ocular pain occurring after ophthalmic sur…

Read the full story

Wednesday, January 04, 2017 | Cataract Surgery, Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Announces Additional Successful Results for Phase 3 Clinical Trial of Dextenza

Ocular Therapeutix announced additional positive secondary endpoint results from its most recent successful phase 3 clinical trial of Dextenza (dexamethasone insert) 0.4 mg for the treatment of postsu…

Read the full story

Monday, November 14, 2016 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Announces Successful Topline Results for Both Inflammation and Pain in Phase 3 Clinical Trial of Dextenza

Ocular Therapeutix announced positive topline results from its phase 3 clinical trial of Dextenza (dexamethasone insert) 0.4 mg for the treatment of postsurgical ocular inflammation and pain. Dextenza…

Read the full story

Friday, October 21, 2016 | Management/Leadership, Ocular Therapeutix

Ocular Therapeutix Appoints Andy Hurley Chief Commercial Officer

Ocular Therapeutix announced the appointment of Andy Hurley to the newly created position of chief commercial officer, effective immediately. In this role, Mr. Hurley will be responsible for leading O…

Read the full story

Thursday, October 13, 2016 | Partnerships, Retina, Ocular Therapeutix, Regeneron Pharmaceuticals

Ocular Therapeutix and Regeneron Collaborate to Develop a Sustained-Release Formulation of Aflibercept for Wet AMD and Other Retinal Diseases

In a deal that could be worth more than $300 million, Ocular Therapeutix announced that it has entered into a strategic collaboration, option, and license agreement with Regeneron Pharmaceuticals to c…

Read the full story

Wednesday, October 05, 2016 | Clinical Trials, Glaucoma, Ocular Therapeutix

Ocular Therapeutix Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP for the Treatment of Glaucoma and Ocular Hypertension

Ocular Therapeutix announced the enrollment of the first patient in the first of two planned phase 3 clinical trials with OTX-TP (sustained release travoprost) for the treatment of glaucoma and ocular…

Read the full story

Thursday, August 04, 2016 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Provides Update on NDA for Dextenza for the Treatment of Postsurgical Ocular Pain

Ocular Therapeutix provided an update on the status of its new drug application (NDA) for Dextenza (dexamethasone insert) 0.4 mg, for intracanalicular use in the treatment of ocular pain occurring aft…

Read the full story

Monday, July 25, 2016 | Clinical Trials, Ocular Therapeutix

FDA Does Not Approve Ocular Therapeutix's Dextenza for Postoperative Pain, Citing Manufacturing Deficiencies

Ocular Therapeutix announced that the FDA did not approve its new drug application for Dextenza (dexamethasone insert) 0.4 mg, for intracanalicular use in the treatment of ocular pain occurring after …

Read the full story

Monday, June 06, 2016 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Does Not Achieve Primary Endpoint in Second Phase 3 Clinical Trial of Dextenza for the Treatment of Allergic Conjunctivitis

Ocular Therapeutix announced topline results from its second phase 3 clinical trial to evaluate the safety and efficacy of Dextenza (sustained-release dexamethasone) Intracanalicular Depot for the tre…

Read the full story

Thursday, April 28, 2016 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP for Glaucoma and Ocular Hypertension

Ocular Therapeutix announced that it has completed its end-of-phase 2 review with the FDA for its OTX-TP (sustained-release travoprost) product candidate for the treatment of glaucoma and ocular hyper…

Read the full story

Tuesday, February 16, 2016 | Clinical Trials, Glaucoma, Ocular Therapeutix

Ocular Therapeutix Announces Phase 3 Clinical Development Plan for Glaucoma Therapy Candidate, OTX-TP

Ocular Therapeutix announced the phase 3 clinical development strategy for its OTX-TP (sustained-release travoprost) drug product candidate for the treatment of glaucoma and ocular hypertension. Based…

Read the full story

Monday, January 11, 2016 | Management/Leadership, Ocular Therapeutix

Ocular Therapeutix Appoints Jonathan H. Talamo, MD, as Chief Medical Officer

Ocular Therapeutix announced the appointment of Jonathan H. Talamo, MD, to the position of chief medical officer. In this role, Dr. Talamo will help advance Ocular’s development pipeline, includ…

Read the full story

Monday, December 14, 2015 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Announces Topline Results from Exploratory Phase 2 Trial for Dextenza in Patients with Inflammatory Dry Eye Disease

Ocular Therapeutix announced topline results from a phase 2 exploratory clinical trial designed to evaluate a range of objective and subjective measures (signs and symptoms, respectively) for Dextenza…

Read the full story
Load More